Management of impulse control disorders in Parkinson's disease: Controversies and future approaches
暂无分享,去创建一个
Angelo Antonini | Michael Samuel | A. Lang | M. Rodriguez-Oroz | M. Okun | J. Brotchie | M. Samuel | K. Ray Chaudhuri | A. Antonini | W. Galpern | Jonathan M. Brotchie | Richard G. Brown | Kallol Ray Chaudhuri | Anthony E. Lang | Michael S. Okun | Maria Rodriguez‐Oroz | Wendy R. Galpern | Melissa J. Nirenberg | M. Nirenberg | Richard G. Brown
[1] R. Brown,et al. Behavioural disorders, Parkinson's disease, and subthalamic stimulation , 2002, Journal of neurology, neurosurgery, and psychiatry.
[2] J. Lisman,et al. The Hippocampal-VTA Loop: Controlling the Entry of Information into Long-Term Memory , 2005, Neuron.
[3] J. Brotchie,et al. The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[4] A. Berney,et al. Rapid Resolution of Dopamine Dysregulation Syndrome (DDS) After Subthalamic DBS for Parkinson Disease (PD): A Case Report , 2008, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.
[5] Zhentao Zhang,et al. Impulsive and Compulsive Behaviors in Parkinson’s Disease , 2014, Front. Aging Neurosci..
[6] K. Chaudhuri,et al. European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD , 2012 .
[7] Martin N. Rossor,et al. Advanced online publication. , 2005, Nature structural biology.
[8] Catechol‐O‐Methyltransferase Genotype Modulates Opioid Release in Decision Circuitry , 2013, Clinical and translational science.
[9] H. Bowden-Jones,et al. Pathological gambling and the treatment of psychosis with aripiprazole: case reports , 2011, British Journal of Psychiatry.
[10] Paul Krack,et al. Mirthful laughter induced by subthalamic nucleus stimulation , 2001, Movement disorders : official journal of the Movement Disorder Society.
[11] Ji Hyun Ko,et al. Dopamine‐agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions , 2014, Human brain mapping.
[12] P. Calabresi,et al. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease , 2013, The Lancet Neurology.
[13] A. Lang,et al. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine , 2012, Movement disorders : official journal of the Movement Disorder Society.
[14] M. Okun,et al. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? , 2013, Movement disorders : official journal of the Movement Disorder Society.
[15] T. Banaschewski,et al. Genetics of preparation and response control in ADHD: the role of DRD4 and DAT1. , 2014, Journal of child psychology and psychiatry, and allied disciplines.
[16] A. Rotondo,et al. Clozapine for medication‐related pathological gambling in Parkinson disease , 2010, Movement Disorders.
[17] Keith Wheatley,et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial , 2010, The Lancet Neurology.
[18] Mark Stacy,et al. Clinical spectrum of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[19] D. Bowers,et al. Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. , 2011, The Journal of neuropsychiatry and clinical neurosciences.
[20] A. Cunnington,et al. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. , 2012, Parkinsonism & related disorders.
[21] L. Tremblay,et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.
[22] R. Roth,et al. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys , 1999, Psychopharmacology.
[23] J. Kulisevsky,et al. Mania following deep brain stimulation for Parkinson's disease. , 2002, Neurology.
[24] D. Stein,et al. Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents , 2000, Depression and anxiety.
[25] A. Grace,et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[26] D. Consoli,et al. Opioid Antagonist Naltrexone for the Treatment of Pathological Gambling in Parkinson Disease , 2012, Clinical neuropharmacology.
[27] P. Christos,et al. Prospective cohort study of impulse control disorders in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[28] J. Brotchie,et al. Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.
[29] Ji Hyun Ko,et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study , 2012, Neurobiology of Disease.
[30] K. Lyons,et al. Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects , 2010, Clinical neuropharmacology.
[31] A. Akyol,et al. Quetiapine in a case with Parkinson disease and pathological gambling. , 2007, Journal of clinical psychopharmacology.
[32] G. Deuschl,et al. A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.
[33] M. Mata,et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[34] C. Baumann,et al. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. , 2012, Parkinsonism & related disorders.
[35] M. Jahanshahi,et al. Parkinson's Disease, the Subthalamic Nucleus, Inhibition, and Impulsivity , 2015, Movement disorders : official journal of the Movement Disorder Society.
[36] E. Granieri,et al. Explosive-aggressive behavior related to bilateral subthalamic stimulation. , 2004, Parkinsonism & related disorders.
[37] H. Berendse,et al. Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin? , 2014, Neuroscience & Biobehavioral Reviews.
[38] J A Tischfield,et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Matsumoto,et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. , 2005, Parkinsonism & related disorders.
[40] F. Limosin,et al. Manic episode with psychotic symptoms in a patient with Parkinson's disease treated by subthalamic nucleus stimulation: Improvement on switching the target , 2008, Journal of the Neurological Sciences.
[41] K. Chaudhuri,et al. Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease , 2013 .
[42] Y. Agid,et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior , 2007, Proceedings of the National Academy of Sciences.
[43] P. A. House,et al. Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trial , 2009 .
[44] S. Fox,et al. Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease , 2013, Neurotherapeutics.
[45] Matteo Pizzorno,et al. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. , 2007, Parkinsonism & related disorders.
[46] A. Jackson,et al. Psychological therapies for pathological and problem gambling. , 2012, The Cochrane database of systematic reviews.
[47] A. Lang,et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study , 2010, Annals of neurology.
[48] D. Riley. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. , 2002, Clinical neuropharmacology.
[49] A. Lang,et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.
[50] V. Shanker,et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. , 2015, Neurology.
[51] B. Bloem,et al. Letters to the Editor Related to New Topics Reversible Parkinsonism After Chronic Cyclosporin Treatment in Renal Transplantation , 2009 .
[52] A. Strafella,et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[53] A. Lawrence,et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease , 2009, Journal of Clinical Neuroscience.
[54] W. Fratta,et al. Differential effect of opioid and cannabinoid receptor blockade on heroin‐seeking reinstatement and cannabinoid substitution in heroin‐abstinent rats , 2011, British journal of pharmacology.
[55] J. Friedman,et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.
[56] M. Nirenberg,et al. Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.
[57] P. Svenningsson,et al. EuroInf: A Multicenter Comparative Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[58] M Tagliati,et al. Subthalamic deep brain stimulation and impulse control in Parkinson’s disease , 2009, European journal of neurology.
[59] Eric Seigneuret,et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. , 2012, Brain : a journal of neurology.
[60] M. Mark,et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. , 2011, The American journal of psychiatry.
[61] A. David,et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers , 2013, Neurology.
[62] J. Régis,et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[63] P. Keck,et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. , 2008, The Journal of clinical psychiatry.
[64] J. Brotchie,et al. α1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques , 2009, Journal of Pharmacology and Experimental Therapeutics.
[65] Pablo Mir,et al. Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[66] J. Friedman,et al. Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[67] JaneR . Taylor,et al. Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task , 2014, Behavioural Brain Research.
[68] S. Owen,et al. Stroke services, stroke networks: is there an ideal model? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[69] C. Honey,et al. Hypomania as an adverse effect of subthalamic nucleus stimulation: report of two cases , 2006, Acta Neurochirurgica.
[70] Trevor W Robbins,et al. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats , 2008, Nature Protocols.
[71] H. Steiger,et al. Cognitive-Behavioral Therapy for Pathological Gambling in Parkinson’s Disease: A Pilot Controlled Study , 2012, European Addiction Research.
[72] M. Onofrj,et al. Pathological gambling in Parkinson disease is reduced by amantadine , 2010, Annals of neurology.
[73] J. Brotchie,et al. Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.
[74] David Garcia-Garcia,et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. , 2011, Brain : a journal of neurology.
[75] Antonio Daniele,et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[76] M. Nirenberg. Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care , 2013, Drugs & Aging.
[77] A. David,et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. , 2012, Parkinsonism & Related Disorders.
[78] G. Deuschl,et al. Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.
[79] K. Kieburtz,et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.
[80] E. López‐Valdés,et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[81] Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. , 2013, Parkinsonism & related disorders.
[82] S. Houle,et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.
[83] Michael S. Okun,et al. Effects of STN and GPi Deep Brain Stimulation on Impulse Control Disorders and Dopamine Dysregulation Syndrome , 2012, PloS one.
[84] A. Antonini. Continuous dopaminergic stimulation--from theory to clinical practice. , 2007, Parkinsonism & related disorders.
[85] J. Régis,et al. Addiction in Parkinson's disease: Impact of subthalamic nucleus deep brain stimulation , 2005, Movement disorders : official journal of the Movement Disorder Society.
[86] Y. Agid,et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation , 2006, Movement disorders : official journal of the Movement Disorder Society.
[87] A. David,et al. Managing impulse control behaviours in Parkinson's disease: practical guidelines. , 2013, British journal of hospital medicine.
[88] E. Foncke,et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[89] Valerie Voon,et al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[90] J. Schneider,et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. , 2010, The international journal of neuropsychopharmacology.
[91] J. Friedman,et al. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. , 1995, The Journal of clinical psychiatry.
[92] J. Brotchie,et al. L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2012, Journal of Pharmacology and Experimental Therapeutics.
[93] Marios Politis,et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.
[94] M. Hallett,et al. Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors , 2010, Neuron.